Sherin Panikulam

After completing her Bachelor and Master studies in Biochemistry at the University of Zurich, Sherin proceeded with her employment at Novartis Pharma AG. In the Bioanalytics department, she supported the characterization of biopharmaceuticals in clinical development by developing, validating and performing bioanalytical assays. In addition, she conducted LC-MS/MS experiments to identify and quantify host cell proteins (HCPs) present in biologics. These projects taught her the necessity of an in-depth risk assessment of product quality. As certain quality attributes can affect stability, activity and immunogenicity of biopharmaceuticals and cause major setbacks in drug development processes.

Her PhD-project, realized in co-operation with FHNW and an industrial partner, allows her to immerse deeper into this increasingly vital topic. This collaborative venture provides a great opportunity to interact and exchange with experts from various scientific fields. Furthermore, it enables her to work on an industrial relevant research topic using state-of-the-art technologies, both in an industrial and academic setting, thereby providing a bilateral perspective.